Updates in the Management of Neuromyelitis Optica Spectrum Disorder Care (NMOSD)

Aaron Miller, MD, FAAN, provides an overview of neuromyelitis optica spectrum disorder (NMOSD).

Flavia Nelson, MD, and Robert Shin, MD, FAAN, provide insight on the forms of neuromyelitis optica spectrum disorder and how its attacks differ from multiple sclerosis.

Aaron Miller, MD, FAAN, reviews the pathophysiology of neuromyelitis optica spectrum disorder and the role of aquaporin-4 in the disease pathway.

Experts in neurology discuss the progression of neuromyelitis optica spectrum disorder, focusing on acute relapse and pseudo attacks.

Expert neurologists review treatment goals in patients with neuromyelitis optica spectrum disorder and share insights on long-term disease-modifying therapies.

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller discuss the current neuromyelitis optica spectrum disorder treatment landscape.

Experts in neurology discuss newly approved medications in the treatment of neuromyelitis optica spectrum disorder, including inebilizumab, eculizumab, and satralizumab.

With a plethora of new treatments for NMOSD, a panel discusses safety concerns.

Robert Shin, MD, FAAN, discusses the potential advantages of using inebilizumab over rituximab in the treatment of NMOSD.

Neurology experts expand on advantages and disadvantages of using FDA-approved treatment compared with other therapy options for neuromyelitis optica spectrum disorder.

Experts in neurology comment on disability and hospitalization rates of NMOSD, as well as how they approach treatment of NMOSD in clinical practice.

Drs Brian Weinshenker, Flavia Nelson, Robert Shin, and Aaron Miller review the unmet needs in the treatment of NMOSD as well as hopes for the future.

Experts in neurology discuss immune tolerance as an alternative strategy and share practice pearls for approaching treatment of NMOSD.